PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Geriatric assessment exposes hidden vulnerabilities in older heart failure patients

heart failureolder adultscomprehensive geriatric assessmentfrailtypolypharmacysarcopeniacognitive impairmentmalnutritioncross-sectional studygeriatric pharmacydeprescribing Geriatrics / Geriatric Pharmacy

Background Information

Identify hidden vulnerabilities in older adults with heart failure.

Heart failure (HF) in older adults often coexists with multiple geriatric syndromes, complicating their management and care planning. Participants with HF had significantly slower physical performance (Five-Times Sit-to-Stand Test: 12.7 s vs. 11.7 s; p = 0.002), lower functional capacity (SPPB: 10.0 vs. 11.0; p = 0.016), and higher prevalence of frailty (31.5% vs. 18.9%; p = 0.009), cognitive impairment (29.3% vs. 14.3%; p = 0.001), and polypharmacy (88.0% vs. 57.9%; p < 0.001). Incorporating a comprehensive geriatric assessment (CGA) into HF management may identify unrecognized vulnerabilities, allowing for tailored multidisciplinary interventions to improve outcomes. CGA reveals significant unmet needs in older adults with HF, highlighting areas for targeted intervention.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Kiliç C, Demir R, Yilmaz Aykent Ö, Yiğit Z, Küçükdağli P, Özulu Türkmen B, Bahat G, Karan MA

Citation: Kiliç C, Demir R, Yilmaz Aykent Ö, et al. Comprehensive geriatric assessment identifies multidimensional vulnerabilities in older adults with heart failure. Turkish journal of medical sciences. 2026;56(3):687-697. doi:10.55730/1300-0144.6202

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →